The IDPH Viral Hepatitis Program will utilize strategies, activities, and resources associated with this cooperative agreement to conduct viral hepatitis, implement prevention interventions, and to reduce the infectious disease consequences of drug use by improving access to services for people who inject drugs (PWID).
The Viral Hepatitis Surveillance and Prevention Program at the Iowa Department of Public Health (IDPH) intends to achieve several outcomes related to viral hepatitis over the five-year project period. Long term outcomes include reduced viral hepatitis infections, increased access to care for people with viral hepatitis, improved health outcomes for people with viral hepatitis, reduced deaths among people with viral hepatitis, reduced health disparities, decreased overdose deaths, and decreased viral hepatitis infections associated with drug use.
The IDPH will collect, analyze, and monitor surveillance data related to hepatitis A; acute and chronic hepatitis B; and acute, chronic, and perinatal hepatitis C. IDPH will also develop a plan to rapidly detect and respond to outbreaks of hepatitis A, B, and C, and will establish a jurisdictional framework for the outbreak detection and response.
The IDPH will develop an elimination plan in year one that will serve as a blueprint to achieve long-term outcomes and will outline evaluation methods. Additionally, the development of a Viral Hepatitis Advisory Council (TAC) will increase stakeholder engagement and provide guidance to the viral hepatitis program.
The IDPH will increase testing and referral to care. Routine HCV and HBV testing will increase in labs and health systems. Testing will also increase among people who inject drugs (PWID) in high impact settings. The IDPH will also increase provider capacity to threat HCV and HBV and will build systemic intervention to increase the number of people referred and linked to medical care.
Through component 3, the IDPH will increase access s for people who inject drugs (PWID) to evidence-based prevention interventions and the “PWID service-bundle”; reduce viral hepatitis, HIV, and other infections, reduce drug-related overdoses; and improve health outcomes for PWID.